Genprex Expands Clinical Trial Sites For Acclaim-3 Clinical Study Of Reqorsa Therapy In Combination With Tecentriq For Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Genprex is expanding its clinical trial sites for the Acclaim-3 clinical study, which tests Reqorsa Therapy in combination with Tecentriq for treating small cell lung cancer. This expansion is in collaboration with a large network of community-based oncology practices. The Acclaim-3 study has received support from the FDA in the form of Orphan Drug and Fast Track Designations.
April 03, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex is expanding its clinical trial sites for the Acclaim-3 study of Reqorsa Therapy in combination with Tecentriq, supported by FDA Orphan Drug and Fast Track Designations.
The expansion of clinical trial sites for Genprex's Acclaim-3 study is a positive development, indicating progress in the clinical trial process. The support from the FDA through Orphan Drug and Fast Track Designations underscores the potential of Reqorsa Therapy in combination with Tecentriq. This news is likely to be viewed positively by investors, as it demonstrates Genprex's commitment to advancing its pipeline and could potentially speed up the time to market for Reqorsa Therapy.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100